The fampridine market was valued at USD 5.38 million in 2025 and is forecast to register a 7.3% CAGR between 2026 and 2036. In 2026, multiple sclerosis (walking improvement) holds 85.1% of application sales, powder represents 72.9% within the form segment and direct accounts for 71.3% of the sales channel category.